Global Ocular Drug Delivery Technology Market Insights:
Limited bioavailability of drugs in conventional ocular therapeutics shall spur research in developing advanced drug delivery techniques for ophthalmic administration. Studies have shown that micellar formulations can help improve bioavailability of drugs in ocular tissues. This shall translate in enhanced therapeutic outcomes. Further, Studies indicate that the number of glaucoma patients is anticipated to rise to 111.8 million by 2040. Based on the aforementioned trends, the global ocular drug delivery technology market is poised to leverage positively at a CAGR of 7.2% during the forecast period (2020-2025).
Global Ocular Drug Delivery Technology Market Technological Insights: Topical drug delivery technology accounted for more than half of the total ocular drug delivery market in 2017. This trend is anticipated to continue, with the topical segment capturing a similar proportion of the overall market. A valuation of US$ 9 Bn is predicted by 2025. Introduction of emulsion and suspension forms in the formulation of topical drug delivery technologies is a major growth driver. Moreover, the technique is also very cost-effective. The topical segment is poised to expand 1.4x throughout the forecast period.
Following behind topical drug delivery is the intraocular implants segment. High adoption of intraocular implants due to its targeted action and long-term effectiveness have boosted growth opportunities for this technology. A market share of more than one-tenth is anticipated for intraocular implants, expanding at a CAGR of 7.7% across the forecast period. The segment is poised to reach a value of US$ 3 Bn by 2025-end.
Global Ocular Drug Delivery Technology Market Formulation Insights: Augmenting demand for targeted drug delivery, especially for posterior eye disorders, and high penetration of low molecular size particles shall leverage market prospects for liposome and nanoparticle formulations. Moreover, nanoparticles are claimed to provide prolonged resistance time on the ocular surface. A CAGR of 8.2% is anticipated for the liposome and nanoparticle segment, reaching a value of US$ 1 Bn by 2025-end.
The solutions segment is set to retain its market dominance across the forecast period. Dominance of the segment is attributed to its large production volume by small players in regional markets. Moreover, high-patient compliance and cost-effectiveness are other growth contributors. Projections indicate a market share exceeding three-fifths and an expansion rate of 1.4x in the forecast period.
To get the latest COVID-19 impact insights on the ocular drug delivery technology, ask an analyst here
Global Ocular Drug Delivery Technology Market Regional Insights:
North America is poised to retain hegemony in the global ocular drug delivery technology market. Burgeoning cases of visual impairments, high cost of ocular surgeries and presence of a large number of market players are anticipated to boost the North American market. Projections indicate a market share exceeding half of the total ocular drug delivery technology market. In addition, introduction of different formulation types and reduced research and development costs are also poised to leverage growth prospects. The North American market is anticipated to expand 1.4x during the forecast period.
Asia-Pacific is expected to generate credible growth opportunities in the future. Establishment of research and development units by key manufacturers in emerging economies, increasing prevalence of cataract and uveitis are key growth levers. Research grants are being advanced by major research companies across several Asia-Pacific countries, thus broadening the scope of drug development. The Asia-Pacific region is poised to expand at a CAGR of 7.0% throughout the forecast period, capturing nearly 1/10th of the total market share.
To get detailed insights on the ocular drug delivery technology market, request for a report sample here
Global Ocular Drug Delivery Technology Market Key Players
The global ocular drug delivery market is consolidated, consisting of a limited number of market players. However, the market is poised to become fragmented, owing to collaboration and acquisition strategies adopted by leading players. The prominent market players are Ocular Therapeutix, Inc., Alimera Sciences, Allergan plc, Valeant Pharmaceuticals International (Bausch Health Company), Inc., and Santen Pharmaceutical Co., Ltd. Specific research and development in ocular drug delivery technologies is an important approach adopted by the leading market players.
Valeant Pharmaceuticals (Bausch & Lomb, Inc.) is a leader in the ocular drug delivery market. It specializes in a number of ophthalmic drugs for a number of conditions. These include glaucoma, conjunctivitis, uveitis and cataracts. Its brands are Bepreve, Istalol, Besivance, Alrex and Zylet. In 2017, the company announced the introduction of Biotrue ONEday, daily disposable contact lenses for Astigmatism. Another market leader, Santen pharmaceuticals, specializes in corneal and retinal diseases such as Dry Eyes, Uveitis, AMD and Diabetic Retinopathy, and Glaucoma. Its products include Tafluprost, Ciclosporin, Sepetaprost and Carotuximab.
COVID-19 Market Insights:
The outbreak of the COVID-19 pandemic has posed significant challenges to the healthcare industry across the globe. As the number of cases rise exponentially every day, key market players are increasingly diverting research and funding towards eradicating this deadly pandemic. This is anticipated to lead to shortfalls in the core business line. However, companies are putting their best feet forward to ensure that supply chains are not disrupted.
Santen pharmaceuticals, a prominent ocular drug player, is ensuring that there is continuous treatment delivery for visually impaired patients. Maintenance of appropriate inventory standards of intermediaries and raw materials is an important step in this regard. Moreover, production plants have been sterilized so that the infection does not spread among factory workers. Thorough body temperature checks along with social distancing are being practiced in the company’s factories. People who are not engaged in production activity are encouraged to work from home. Furthermore, all employees have been strongly discouraged to travel abroad for work.
Another market player, Graybug Vision, has directed its patients who are enrolled in clinical studies to restrict their in-clinic time to reduce exposure risk. Since most of the subjects are elderly patients, this precaution is absolutely important. This is anticipated to lead to substantial delays in drug development for visual disorders.
Analyst’s Viewpoint:
The global ocular drug delivery market shall witness positive growth in the future. Technological breakthroughs in the form of novel drug formulations for precise ophthalmic treatment is are poised to leverage the market. However, the ongoing COVID-19 pandemic shall substantially impede progress, owing to reduced production and research capabilities. However, in the long-run, the market is set to rebound. North America and Asia-Pacific are poised to remain attractive markets for ocular drug delivery. This is due to increasing research funding by the governments of the respective countries.
Global Ocular Drug Delivery Technology Market: Report Scope:
The study of the global ocular drug delivery technology market undertaken by Fact.MR, incorporates a five-year forecast period, 2020-2025. The report explicates on the key drivers, restraints and opportunities associated with ocular drug delivery. The market has been segmented on the basis of technology type, formulation type, disease type and end-user. Each segment is evaluated in terms of market share, revenue, attractiveness index and growth.
A detailed regional profiling has also been done, incorporating all of the abovementioned segments. The profiling is done for the following geographies: North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. In addition, a detailed competition landscape, highlighting key manufacturers’ revenue share, expansion strategies and product launches, have also been embedded within the report. Each company is also provided with a SWOT analysis to provide a realistic picture for future expansion.
Global Ocular Drug Delivery Technology Market- Scope of the Report
The recent study by Fact.MR on global ocular drug delivery technology market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends currently determining the growth of the global ocular drug delivery technology market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the provision of global ocular drug delivery technology. The study also provides dynamics responsible for influencing the future status of the global ocular drug delivery technology market over the forecast period.
A detailed assessment of the global ocular drug delivery technology market’s value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global ocular drug delivery technology market along with their product portfolio enhances the reliability of this comprehensive research study.
Global Ocular Drug Delivery Technology Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global ocular drug delivery technology market across the globe.
A comprehensive estimate on the global ocular drug delivery technology market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of global ocular drug delivery technology market during the forecast period.
Global Ocular Drug Delivery Technology Market Segmentation
Fact.MR has studied the global ocular drug delivery technology market with detailed segmentation on the basis of technology type, formulation type, disease type, end-user and region.
|
Technology Type |
Formulation Type |
Disease Type |
End-user |
Region |
|
Topical |
Solution |
Glaucoma |
Hospitals |
North America |
|
Ocular Inserts: Non-erodible Erodible |
Suspension |
Diabetic Retinopathy |
Ambulatory Surgical Centers |
Europe |
|
Iontophoresis |
Emulsion |
Dry Eye Syndrome |
Ophthalmic Clinics |
Asia Pacific |
|
Intraocular Implants: Biodegradable Non-biodegradable |
Liposomes & Nanoparticles |
Macular Degeneration |
Homecare Settings |
Latin America |
|
In-Situ Gel & Punctal Plugs |
Ointment |
Diabetic Macular Edema |
|
Middle East & Africa |
|
Others |
|
Cataract |
|
|
|
|
|
Others |
|
|
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Global Ocular Drug Delivery Technology Market: Analysis on Market Size Evaluation
The global ocular drug delivery technology market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for global ocular drug delivery technology market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent global ocular drug delivery technology market segments, along with market attractiveness evaluation has been incorporated in the report.
Global Ocular Drug Delivery Technology Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the global ocular drug delivery technology report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global ocular drug delivery technology market during the forecast period.
Country-specific valuation on demand for global ocular drug delivery technology has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Global Ocular Drug Delivery Technology Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of global ocular drug delivery technology products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global ocular drug delivery technology products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global ocular drug delivery technology market. Prominent manufacturers with established market presence in the global ocular drug delivery technology market are Ocular Therapeutix, Inc., Alimera Sciences, Allergan plc, Valeant Pharmaceuticals International (Bausch Health Company), Inc., and Santen Pharmaceutical Co., Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ocular Drug Delivery Disease Type Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/Disease Type Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, 2020–2025
4.6. Ocular Drug Delivery Disease Type Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Market Outlook
4.9. Ocular Drug Delivery Technology: Pipeline Analysis
5. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, By Disease Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast By Disease Type, 2020–2025
5.4.1. Topical
5.4.2. Ocular Insert
5.4.2.1. Erodible
5.4.2.2. Non-Erodible
5.4.3. Iontophoresis
5.4.4. Intraocular Implant
5.4.4.1. Biodegradable
5.4.4.2. Non-Biodegradable
5.4.5. In Situ Gel & Punctal Plug
5.4.6. Others
5.5. Market Attractiveness By Disease Type
6. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, By Formulation Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast By Formulation Type, 2020–2025
6.4.1. Solution
6.4.2. Suspension
6.4.3. Emulsion
6.4.4. Liposomes & Nanoparticles
6.4.5. Ointments
6.5. Market Attractiveness By Formulation Type
7. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, By Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast By Disease Type , 2020–2025
7.4.1. Diabetic Retinopathy
7.4.2. Macular Degeneration
7.4.3. Cataract
7.4.4. Glaucoma
7.4.5. Diabetic Macular Edema
7.4.6. Dry Eye Syndrome
7.4.7. Others
7.5. Market Attractiveness By Disease Type
8. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, By End User
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Value Forecast By End User, 2020–2025
8.4.1. Hospitals
8.4.2. Ambulatory Surgical Centers
8.4.3. Ophthalmic Clinics
8.4.4. Homecare Settings
8.5. Market Attractiveness By End User
9. Global Ocular Drug Delivery Disease Type Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Value Forecast By Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness By Country/Region
10. North America Ocular Drug Delivery Disease Type Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Value Forecast By Disease Type, 2020–2025
10.2.1. Topical
10.2.2. Ocular Insert
10.2.2.1. Erodible
10.2.2.2. Non-Erodible
10.2.3. Iontophoresis
10.2.4. Intraocular Implant
10.2.4.1. Biodegradable
10.2.4.2. Non-Biodegradable
10.2.5. In Situ Gel & Punctal Plug
10.2.6. Others
10.3. Market Value Forecast By Formulation Type, 2020–2025
10.3.1. Solution
10.3.2. Suspension
10.3.3. Emulsion
10.3.4. Liposomes & Nanoparticles
10.3.5. Ointments
10.4. Market Value Forecast By Disease Type, 2020–2025
10.4.1. Diabetic Retinopathy
10.4.2. Macular Degeneration
10.4.3. Cataract
10.4.4. Glaucoma
10.4.5. Diabetic Macular Edema
10.4.6. Dry Eye Syndrome
10.4.7. Others
10.5. Market Value Forecast By End User, 2020–2025
10.5.1. Hospitals
10.5.2. Ambulatory Surgical Centers
10.5.3. Ophthalmic Clinics
10.5.4. Homecare Settings
10.6. Market Value Forecast By Country, 2020–2025
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease Type
10.7.2. By Formulation Type
10.7.3. By Disease Type
10.7.4. By End User
10.7.5. By Country
11. Europe Ocular Drug Delivery Disease Type Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2. Market Value Forecast By Disease Type, 2020–2025
11.2.1. Topical
11.2.2. Ocular Insert
11.2.2.1. Erodible
11.2.2.2. Non-Erodible
11.2.3. Iontophoresis
11.2.4. Intraocular Implant
11.2.4.1. Biodegradable
11.2.4.2. Non-Biodegradable
11.2.5. In Situ Gel & Punctal Plug
11.2.6. Others
11.3. Market Value Forecast By Formulation Type, 2020–2025
11.3.1. Solution
11.3.2. Suspension
11.3.3. Emulsion
11.3.4. Liposomes & Nanoparticles
11.3.5. Ointments
11.4. Market Value Forecast By Disease Type, 2020–2025
11.4.1. Diabetic Retinopathy
11.4.2. Macular Degeneration
11.4.3. Cataract
11.4.4. Glaucoma
11.4.5. Diabetic Macular Edema
11.4.6. Dry Eye Syndrome
11.4.7. Others
11.5. Market Value Forecast By End User, 2020–2025
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Ophthalmic Clinics
11.5.4. Homecare Settings
11.6. Market Value Forecast By Country, 2020–2025
11.6.1. U.K.
11.6.2. Germany
11.6.3. France
11.6.4. Italy
11.6.5. Russia
11.6.6. Spain
11.6.7. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease Type
11.7.2. By Formulation Type
11.7.3. By Disease Type
11.7.4. By End User
11.7.5. By Country
12. Asia Pacific Ocular Drug Delivery Disease Type Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2. Market Value Forecast By Disease Type, 2020–2025
12.2.1. Topical
12.2.2. Ocular Insert
12.2.2.1. Erodible
12.2.2.2. Non-Erodible
12.2.3. Iontophoresis
12.2.4. Intraocular Implant
12.2.4.1. Biodegradable
12.2.4.2. Non-Biodegradable
12.2.5. In Situ Gel & Punctal Plug
12.2.6. Others
12.3. Market Value Forecast By Formulation Type, 2020–2025
12.3.1. Solution
12.3.2. Suspension
12.3.3. Emulsion
12.3.4. Liposomes & Nanoparticles
12.3.5. Ointments
12.4. Market Value Forecast By Disease Type, 2020–2025
12.4.1. Diabetic Retinopathy
12.4.2. Macular Degeneration
12.4.3. Cataract
12.4.4. Glaucoma
12.4.5. Diabetic Macular Edema
12.4.6. Dry Eye Syndrome
12.4.7. Others
12.5. Market Value Forecast By End User, 2020–2025
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Ophthalmic Clinics
12.5.4. Homecare Settings
12.6. Market Value Forecast By Country, 2020–2025
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease Type
12.7.2. By Formulation Type
12.7.3. By Disease Type
12.7.4. By End User
12.7.5. By Country
13. Latin America Ocular Drug Delivery Disease Type Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Price Trend Analysis
13.1.4. Key Trends
13.2. Market Value Forecast By Disease Type, 2020–2025
13.2.1. Topical
13.2.2. Ocular Insert
13.2.2.1. Erodible
13.2.2.2. Non-Erodible
13.2.3. Iontophoresis
13.2.4. Intraocular Implant
13.2.4.1. Biodegradable
13.2.4.2. Non-Biodegradable
13.2.5. In Situ Gel & Punctal Plug
13.2.6. Others
13.3. Market Value Forecast By Formulation Type, 2020–2025
13.3.1. Solution
13.3.2. Suspension
13.3.3. Emulsion
13.3.4. Liposomes & Nanoparticles
13.3.5. Ointments
13.4. Market Value Forecast By Disease Type, 2020–2025
13.4.1. Diabetic Retinopathy
13.4.2. Macular Degeneration
13.4.3. Cataract
13.4.4. Glaucoma
13.4.5. Diabetic Macular Edema
13.4.6. Dry Eye Syndrome
13.4.7. Others
13.5. Market Value Forecast By End User, 2020–2025
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Ophthalmic Clinics
13.5.4. Homecare Settings
13.6. Market Value Forecast By Country, 2020–2025
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease Type
13.7.2. By Formulation Type
13.7.3. By Disease Type
13.7.4. By End User
13.7.5. By Country
14. Middle East & Africa Ocular Drug Delivery Disease Type Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.1.2. Policies and Regulations
14.1.3. Price Trend Analysis
14.1.4. Key Trends
14.2. Market Value Forecast By Disease Type, 2020–2025
14.2.1. Topical
14.2.2. Ocular Insert
14.2.2.1. Erodible
14.2.2.2. Non-Erodible
14.2.3. Iontophoresis
14.2.4. Intraocular Implant
14.2.4.1. Biodegradable
14.2.4.2. Non-Biodegradable
14.2.5. In Situ Gel & Punctal Plug
14.2.6. Others
14.3. Market Value Forecast By Formulation Type, 2020–2025
14.3.1. Solution
14.3.2. Suspension
14.3.3. Emulsion
14.3.4. Liposomes & Nanoparticles
14.3.5. Ointments
14.4. Market Value Forecast By Disease Type, 2020–2025
14.4.1. Diabetic Retinopathy
14.4.2. Macular Degeneration
14.4.3. Cataract
14.4.4. Glaucoma
14.4.5. Diabetic Macular Edema
14.4.6. Dry Eye Syndrome
14.4.7. Others
14.5. Market Value Forecast By End User, 2020–2025
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Ophthalmic Clinics
14.5.4. Homecare Settings
14.6. Market Value Forecast By Country, 2020–2025
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East and Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease Type
14.7.2. By Formulation Type
14.7.3. By Disease Type
14.7.4. By End User
14.7.5. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2015)
15.3. Company Profiles
15.3.1. OCULAR THERAPEUTIX, INC.
15.3.1.1. Overview
15.3.1.2. Financials
15.3.1.3. Recent Developments
15.3.1.4. Strategy
15.3.2. Alimera Sciences
15.3.2.1. Overview
15.3.2.2. Financials
15.3.2.3. Recent Developments
15.3.2.4. Strategy
15.3.3. Allergan, Plc
15.3.3.1. Overview
15.3.3.2. Financials
15.3.3.3. Recent Developments
15.3.3.4. Strategy
15.3.4. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Incorporated)
15.3.4.1. Overview
15.3.4.2. Financials
15.3.4.3. Recent Developments
15.3.4.4. Strategy
15.3.5. EyeGate Pharma
15.3.5.1. Overview
15.3.5.2. Financials
15.3.5.3. Recent Developments
15.3.5.4. Strategy
15.3.6. Envisia Therapeutics
15.3.6.1. Overview
15.3.6.2. Financials
15.3.6.3. Recent Developments
15.3.6.4. Strategy
15.3.7. Clearside Biomedical, INC.
15.3.7.1. Overview
15.3.7.2. Financials
15.3.7.3. Recent Developments
15.3.7.4. Strategy
15.3.8. Graybug Vision Inc.
15.3.8.1. Overview
15.3.8.2. Financials
15.3.8.3. Recent Developments
15.3.8.4. Strategy
15.3.9. Santen Pharmaceutical Co., Ltd
15.3.9.1. Overview
15.3.9.2. Financials
15.3.9.3. Recent Developments
15.3.9.4. Strategy
15.3.10. Taiwan Liposome Company, Ltd
15.3.10.1. Overview
15.3.10.2. Financials
15.3.10.3. Recent Developments
15.3.10.4. Strategy
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Fact.MR in Media
Our analysts in Media
Ocular Drug Delivery Technology Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025